SN-38 Sensitizes BRCA-Proficient Ovarian Cancers to PARP Inhibitors through Inhibiting Homologous Recombination Repair

Figure 2

SN-38 sensitizes BRCA-proficient ovarian cancers to PARP inhibitors. (a) A2780 and OVCAR-3 cells were treated with 2 μM olaparib, 5 nM SN-38, or their combination for 72 hrs, and the cell viability was measured by CCK8. (b, c) Colony formation survival analysis of A2780 and OVCAR-3 cells were treated with the indicated concentration of olaparib and SN-38. Representative colony formations were shown (b) and the relative number of colonies was quantified and normalized to untreated parental cells (c). and , by two-tailed -test.

(a)

(b)

(c)